Opens in a new tab

Dr. Gu Jie Ruo

Chinese name: 古洁若
Professor, Chief Physician, Doctoral Supervisor . Rheumatology & Immunology
Professor Gu Jieruo is academic leader of rheumatology and immunology at the Third Affiliated Hospital of Sun Yat-sen University. A recipient of the National Science Fund for Distinguished Young Scholars, she is a leading authority on ankylosing spondylitis, spondyloarthritis and hyperuricaemia, and directs the Guangdong Clinical Research Centre for Immune Diseases.

Private & confidential

No obligation

Coordinated end-to-end by Orisene

38
Years in clinical practice and teaching
120+
SCI papers published
26
Books and monographs edited

  • The Physician

About Dr. Gu Jie Ruo

Professor Gu Jieruo is academic leader of rheumatology and immunology at the Third Affiliated Hospital of Sun Yat-sen University, Director of the Guangdong Clinical Research Centre for Immune Diseases and Director of the provincial rheumatology quality control centre. She has devoted nearly four decades to rheumatic disease, with particular expertise in ankylosing spondylitis, spondyloarthritis and gout. Her research explores the genetics, single-cell mechanisms and pathological bone formation of ankylosing spondylitis and new biologic therapies, and she has published more than three hundred SCI papers and edited over thirty textbooks. She holds the National Science Fund for Distinguished Young Scholars and the title National Famous Doctor.
1、Academic leader of rheumatology and immunology at the Third Affiliated Hospital of Sun Yat-sen University
2、Director of the Guangdong Clinical Research Centre for Immune Diseases
3、Recipient of the National Science Fund for Distinguished Young Scholars
4、Recipient of the State Council Special Allowance and the title National Famous Doctor
5、Member of the International Expert Committee on Ankylosing Spondylitis
6、Author of more than three hundred SCI papers on rheumatic disease

Dr. Gu Jie Ruo ’s Three Key Areas of Expertise

Three areas of focused expertise, each supported by a deep subspecialty team, high case volumes and an English-speaking care pathway coordinated by Orisene.

Ankylosing spondylitis

She diagnoses and treats ankylosing spondylitis and axial spondyloarthritis, using imaging, HLA-B27 testing and biologic therapy to control inflammation, relieve pain and morning stiffness and prevent progressive spinal fusion and long-term disability for patients living with these chronic inflammatory joint diseases.

Gout and hyperuricaemia

She manages gout and hyperuricaemia with urate-lowering therapy, lifestyle guidance and long-term monitoring, aiming to dissolve urate deposits, prevent recurrent painful attacks and protect the joints and kidneys of patients living with these common metabolic rheumatic conditions in routine clinical practice.

Rheumatoid arthritis and lupus

She treats rheumatoid arthritis, systemic lupus erythematosus and other autoimmune rheumatic diseases with individualised immunosuppressive and biologic therapy, integrating regular clinical assessment and laboratory monitoring to control disease activity and protect the joints and vital organs of patients over the long term.

More： spondyloarthritis——biologic therapy; osteoporosis——management; Sjogren’s syndrome——diagnosis; vasculitis——treatment; autoimmune disease——clinical research

  • Clinical Practice & Publications

Selected cases, research & publications

Representative work drawn from documented clinical treatments, publicly indexed literature, and hospital project records, reflecting the depth of this physician's hands-on expertise and academic rigor.
1. Xeligekimab (IL-17A Antagonist) for Active Radiographic Axial Spondyloarthritis
This phase III randomized, double-blind, placebo-controlled trial assessed Xeligekimab, an interleukin-17A antagonist, in Chinese patients with active radiographic axial spondyloarthritis. The 16- and 48-week results showed clinical benefit, offering an additional biologic option for patients with ankylosing spondylitis and axial spondyloarthritis.
2. AK111 Monoclonal Antibody for Active Ankylosing Spondylitis
This multicenter, randomized, double-blind, placebo-controlled phase II study evaluated the efficacy and safety of the monoclonal antibody AK111 in patients with active ankylosing spondylitis. The trial provides evidence to guide targeted immunotherapy for people with persistent back pain and spinal inflammation.
3. Single-Cell Profiling of Senescent Bone Marrow Stem Cells in Ankylosing Spondylitis
Single-cell profiling identified senescent bone marrow mesenchymal stem cell subpopulations that drive pathological new bone formation in ankylosing spondylitis. The discovery helps rheumatologists understand spinal fusion and may lead to therapies that slow structural damage and spinal fusion in patients with ankylosing spondylitis.
4. PD-L1-Positive Mesenchymal Stem Cells and Ectopic Bone Formation in Ankylosing Spondylitis
Single-cell RNA sequencing identified PD-L1-positive mesenchymal stem cells with enhanced immunomodulatory capacity that alleviated ectopic new bone formation in ankylosing spondylitis. This work suggests immunoregulatory cell-based strategies to reduce abnormal bone growth and improve outcomes for patients with axial spondyloarthritis and spinal inflammation.
5. ANO6 Gene Polymorphism and Ankylosing Spondylitis in a Chinese Han Population
This genetic study analyzed the association of ANO6 gene polymorphism and expression with ankylosing spondylitis in a Chinese Han population. The findings add to understanding of disease susceptibility and may help rheumatologists identify patients at higher risk for early diagnosis and targeted management.
6. A Phthalate Ester-Ankylosing Spondylitis Signature and Inflammatory Monocyte Program
Using a database-derived signature, this research linked phthalate ester exposure to ankylosing spondylitis and identified an AP-1/CXCL8 inflammatory classical-monocyte program. It highlights environmental and immune factors that may guide prevention and personalized treatment for patients with ankylosing spondylitis and axial spondyloarthritis.
  • Affiliated Hospital

Where Dr. Gu Jie Ruo practices

Guangzhou

The Third Affiliated Hospital,Sun Yat-Sen University

Chinese name: 中山大学附属第三医院
The Third Affiliated Hospital of Sun Yat-sen University, a Grade-A tertiary hospital founded in 1971, excels in hepatology, neurology and immunology with 5 national key disciplines, 15 national key specialties, four campuses and nationally leading liver-disease care, serving over 12,000 daily outpatients.
Since 1971
55 years of care
2,000
Licensed beds
15
National key specialties
817
Licensed beds
View Hospital Profile
Appointments with this physician are booked through official hospital channels only, coordinated end-to-end by Orisene.
  • WHY INTERNATIONAL PATIENTS CHOOSE CHINA

Why patients travel to China for treatment

Six reasons international patients now put China on their shortlist — from internationally aligned clinical capability to the policy channels that make treatment here genuinely reachable.

Clinical capability at international standard

Chinese hospitals deliver internationally aligned protocols, performing vast volumes of advanced robotic, minimally invasive, and complex transplant surgeries annually. This massive clinical data and highly specialized workforce ensure world-class outcomes, even for rare and complex cases.

Diagnostics and treatment in days, not months

A full medical workup that typically means months of waiting elsewhere is completed in China within 48–72 hours. Imaging, labs, and multidisciplinary consultations are integrated into a single visit, allowing treatment to commence immediately.

Transparent, itemised pricing

Chinese healthcare offers legally binding, itemised cost estimates before treatment begins, eliminating hidden fees or surprise billing. Due to national centralized procurement, total expenses remain 40–70% lower than comparable care in Western Europe or North America.

Policy channels that open the door

China facilitates access through 240-hour visa-free transit and dedicated medical visa routes. Policies like the Greater Bay Area drug pathway and Boao Lecheng’s pilot zone allow designated hospitals to administer innovative therapies not yet globally approved.
  • International Patient Guide

Consulting this physician, step by step

From the first message to the follow-up after you fly home, one coordinator, no paperwork on your side.
01
Day 0
  • Share your story
    A private consultation with an Orisene advisor, by message, phone or video. Send medical records in any language. Nothing is shared with the hospital yet.
02
Days 1–3
  • Records review & matching
    Orisene translates and presents your case to the right specialist. The hospital returns a tailored care plan, with costs itemised once that plan is confirmed.
03
Days 3–7
  • Your consultation
    Appointments are booked through official hospital channels only. Your navigator accompanies every visit with real-time interpretation, so you can focus on one thing: being cared for.
04
After you fly home
  • Reports & follow-up
    Translated reports and prescriptions delivered within days, remote follow-up coordination with your physicians at home, and a standing line to your navigator.
Orisene offers English and multilingual services, a professional medical interpreter at every consultation, plus translation of your records, reports and prescriptions.

Ready to plan your consultation with Dr. Gu Jie Ruo?

Send your records in any language. An Orisene advisor will reply within 2 hours, present your case to the right specialist, and return a tailored care plan with itemised costs, before anything is booked. Simple. Private. Efficient.
Contact

Confidential, permanently

Independent — no hospital commission

We never handle medical fees

Information Sources

This physician profile is compiled by the Orisene team from publicly available online sources and verified at the time of publication. Details may change, and physician availability is confirmed at the time of booking.

Disclaimer: This information is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personal medical guidance.

Mention of any specific product, brand, or manufacturer is for informational purposes only and does not constitute an endorsement or recommendation by Dr. Gu Jie Ruo.